To address blood transfusion issues, Roche Diagnostics and Apollo Hospitals Enterprise Limited have joined hands to create awareness of the need for safe blood donation and screening to ensure safe blood for transfusion with the #IPledgeRED campaign.

Blood transfusion is a vital component of a healthcare delivery system but there is a huge mismatch between demand and supply. The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year.

The “IPledgeRED” campaign will extend across colleges in 8+ cities to promote voluntary blood donation amongst students of 18 years and above. The “IPledgeRED” initiative will collaborate with colleges across Tamil Nadu, Telangana, Gujarat, Chhattisgarh, Maharashtra, Uttar Pradesh, and Delhi for voluntary blood donation.

The campaign encourages students to donate blood at nearby Apollo Hospital sites and also learn about the safe blood screening practices adopted to ensure safe blood that is free from any infections for recipients. The campaign is supported by the Thalassemia Patient Advocacy Group (TPAG) and Thalassemia India (TI).

Though very low, one of the risks of blood transfusion is that of blood-borne infections causing transfusion-transmitted diseases (TTIs). Conventional screening such as ELISA serology testing requires several days to a few weeks for identifying underlying infections in the donated blood.

The “IPledgeRED” campaign will highlight the role of Nucleic Acid Testing (NAT) which can screen infections that are as recent as 5 days, thereby reducing the risk of transfusion-transmitted diseases (TTIs).

NAT screening is considered the gold standard in blood safety screening and significantly reduces TTIs related to Hepatitis B & C and HIV among others. With NAT screening, transplant recipients, accident victims, cancer patients, and those undergoing major surgery can be assured of safe supplies of blood and plasma for transfusion.

Sangita Reddy, Joint Managing Director, Apollo Hospitals Group said, “Apollo Hospitals has been a pioneer in practicing safe blood donation. We were among the first to adopt NAT testing and have significantly contributed to ensuring safe blood transfusion against transfusion-transmitted viral infections such as HIV, Hepatitis B and Hepatitis C. The processes at our blood banks ensure that both donors and transfusion recipients can rest assured about the safety and quality of blood donation."

"The “IPledgeRED” campaign will make our youngsters aware of how the adoption of NAT can ensure that only the safest blood reaches recipients. With this campaign in association with Roche Diagnostics, we will also educate the medical fraternity at large to advocate for safe blood screening, thus ensuring safe transfusion practices,” added Reddy.

Speaking on the occasion, Narendra Varde, Managing Director, Roche Diagnostics India said, “We are happy to partner with Apollo Hospitals to jointly launch this campaign. At Roche, we feel that access to safe blood should be considered one of the most important pillars of modern-day healthcare. In India, mandatory screening tests that are in practice often cannot detect underlying infections, and hence there is an acute need for an additional layer of most sensitive tests such as nucleic acid testing. We are confident that with the combined power of the network of Apollo Hospitals and Roche Diagnostics’ leadership in the blood and plasma NAT screening market, we will be able to bring safety, reliability, and efficiency to donor screening on a national level.”